Literature DB >> 8907312

Variability in platelet procoagulant activity in healthy volunteers.

W T Sumner1, D M Monroe, M Hoffman.   

Abstract

Blood platelets provide the major surface for thrombin generation. When platelets are activated they expose phosphatidylserine (PS) on their outer membranes, providing the surface on which two procoagulant enzyme complexes, the Xase and prothrombinase complexes, assemble. We hypothesized that there is biological variability in platelet procoagulant activity. To test this hypothesis, we activated isolated platelets from seventeen volunteers, and added plasma concentrations of factors VIII, IXa, and X for the Xase complex assembly, and F.Xa and II for the prothrombinase complex. Xase and prothrombinase activity were assayed using a chromogenic substrate. We found a two- to three-fold variation in Xase and prothrombinase activity, respectively. The distribution of Xase activity in the population was symmetric, while the distribution of prothrombinase activity was positively skewed. The difference in distribution implies that simple expression of procoagulant lipid was not the only determinant of procoagulant activity. Variation in prothrombinase activity was not due to the amount of platelet-released F.V. Neither microparticle production nor F.X binding correlated with Xase or prothrombinase activity. Using fluorescein-conjugated annexin V, we also found no direct correlation between the level of PS exposure and Xase or prothrombinase activity. This indicates that platelets must make other contributions, in addition to PS, to the activity of the Xase and prothrombinase complexes. There is evidence that platelets possess specific receptors for some coagulation proteins, although these receptors have not been isolated. Biological variability in the expression of platelet receptors might explain the differences in Xase and prothrombinase activities in our study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907312     DOI: 10.1016/0049-3848(96)00028-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.

Authors:  Amy D Shapiro; Ulla Hedner
Journal:  Ther Adv Drug Saf       Date:  2011-10

2.  Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition.

Authors:  A L Kuharsky; A L Fogelson
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

Review 3.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

4.  A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.

Authors:  Zoya Volovyk; Dougald M Monroe; YiWei Qi; Richard Becker; Maureane Hoffman
Journal:  J Thromb Thrombolysis       Date:  2009-08       Impact factor: 2.300

5.  Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation.

Authors:  Tracy Stokol; Priscila Beatriz da Silva Serpa; Muhammad N Zahid; Marjory B Brooks
Journal:  Front Vet Sci       Date:  2016-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.